Saturday , 21 April 2018

Home » RESOURCES » INVESTING » Prothena shares jump on Parkinson’s drug study data

Prothena shares jump on Parkinson’s drug study data

SAN FRANCISCO (MarketWatch) — Shares of Prothena Corp. rallied in the extended session Thursday after the biotech said an early-stage study showed its Parkinson’s drug candidate lowered levels of a protein associated with the disease. Prothena shares jumped 38% to $40.20 on moderate volume. The company said the drug PRX002 lowered levels of free serum alpha-synuclein up to 96% in Parkinson’s patients. Alpha-synuclein is potentially involved in the onset and progression of Parkinson’s, the company said.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Prothena shares jump on Parkinson’s drug study data Reviewed by on . SAN FRANCISCO (MarketWatch) -- Shares of Prothena Corp. rallied in the extended session Thursday after the biotech said an early-stage study showed its Parkinso SAN FRANCISCO (MarketWatch) -- Shares of Prothena Corp. rallied in the extended session Thursday after the biotech said an early-stage study showed its Parkinso Rating:
scroll to top